05/03/11 06:18 PM, EDT
The growing use of a popular drug in the long-term treatment of bipolar disorder is based largely on a single, flawed clinical trial that may be steering doctors and patients away from drugs with a more established track record, a new review published this week in the journal "PLoS Medicine"http://www.plosmedicine.org/article/info%3Adoi%2F10.1371%2Fjournal.pmed.1000434
suggests. Read the full story at
Posts
